Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Contact
Description
This study involves an investigational cellular therapy called Afamitresgene Autoleucel. The overall goal of this study is to find out how safe and effective this cellular therapy is in treating people that have been diagnosed with synovial sarcoma, malignant peripheral nerve sheath tumors (MPNST), neuroblastoma or osteosarcoma that has grown or returned after being treated.
Eligibility and criteria
What to expect
The study will enroll male and female patients between 2 and 21 years of age that have been diagnosed with synovial sarcoma, malignant peripheral nerve sheath tumors (MPNST), neuroblastoma or osteosarcoma that has grown or returned after being treated.
As a participant in this research, you will:
- Undergo leukapheresis to remove white blood cells (called T Cells) from your blood
- Receive the cellular therapy called Afamitresgene Autoleucel via infusion. This is manufactured from your T Cells.
- Complete frequent clinic visits at CHOP
- Have research blood tests
- Have extra or leftover tissue collected if you have a biopsy as part of your regular cancer care
- Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.